What this means
Mailing stool test kits to patients at community clinics raised screening at 2 years, but not at 3 years. The difference at 3 years was not statistically significant, so the effect over time is unclear.
Plain-English summary written by an AI model from the abstract. The original is below.
- Who it was tested in
- 20250 patients at 16 clinics in Southern California
- Kind of research
- A clinical trial in people
The science
- Original title
- Fecal Immunochemical Test Outreach for Colorectal Cancer Screening in Community Health Centers: A Randomized Clinical Trial.
- Authors
- Martinez ME, Roesch S, Largaespada V et al.
- Journal
- JAMA network open
- Published
- Oct 22, 2026
- Study type
- Clinical trial · in humans
- PMID
- 42905707 ↗
Abstract
Background
Colorectal cancer (CRC) screening is suboptimal among people in traditionally underserved populations, many of whom receive primary care at federally qualified health centers (FQHCs). Mailed fecal immunochemical test (FIT) outreach improves screening, especially in underserved populations, but questions remain about impact over time. To evaluate the effectiveness of centralized annual mailed FIT outreach delivered over 3 years to increase CRC screening in FQHCs.
What they did
This cluster randomized clinical trial was conducted between June 1, 2021, and May 31, 2024. Sixteen clinics from 2 FQHCs in Southern California were randomly assigned to mailed FIT outreach or usual care for patients aged 50 to 75 years and not up to date with screening. Intervention components followed best practices for mailed FIT outreach and included educational primers, FIT kits, and telephone reminders. The primary outcome was the proportion of individuals up to date with any CRC screening after 3 years of intervention (point prevalence); screening at 2 years was a secondary outcome. Due to a resource constraint-related protocol modification, mailed FIT outreach began earlier in year 3, such that some individuals who completed screening in year 2 were not yet due for repeat FIT.
What they found
Among 16 clinics serving 20 250 patients, 6 clinics serving 8334 individuals at baseline (4435 aged 55-64 years [53.2%]; 4896 female [58.7%]; 341 Asian [4.1%], 238 Black [2.9%], 2390 Hispanic [28.7%], and 4371 non-Hispanic White [52.4%]) were randomized to intervention and 10 clinics serving 11 916 individuals at baseline (6443 aged 55-64 years [54.1%]; 7250 female [60.8%]; 699 Asian [5.9%], 355 Black [3.0%], 4635 Hispanic [38.9%], and 4436 non-Hispanic White [37.2%]) were randomized to usual care. At year 3, screening was 39.4% (95% CI, 36.3% to 42.6%) in intervention clinics vs 36.5% (95% CI, 31.2% to 42.2%) in usual care clinics, which was not a statistically significant difference (2.9 percentage points; 95% CI, -3.2 to 9.0 percentage points). At year 2, screening was 37.8% (95% CI, 35.2% to 40.4%) in intervention clinics vs 27.0% (95% CI, 21.8% to 32.9%) in usual care clinics (difference, 10.8 percentage points; 95% CI, 4.9 to 16.7 percentage points). This study's findings suggest that centralized mailed FIT outreach could increase CRC screening in FQHCs serving populations with persistent disparities, although maintaining intervention fidelity and providing ongoing implementation support over time are needed for consistent impact.
Other details
ClinicalTrials.gov Identifier: NCT04941300.
The authors' abstract, grouped under plain headings from its own section labels.
Martinez ME, Roesch S, Largaespada V et al. Fecal Immunochemical Test Outreach for Colorectal Cancer Screening in Community Health Centers: A Randomized Clinical Trial. JAMA network open. 2026. doi:10.1001/jamanetworkopen.2026.39013. PMID: 42905707. https://pubmed.ncbi.nlm.nih.gov/42905707/
Related research
Lung scan bone density may predict spine fractures in heavy smokers
Researchers checked bone density from lung scans against later spine fractures and deaths. Higher risk showed up for people with low bone density, but this is one older study.
Hormone therapy and menopause timing linked to breast cancer outcomes
Women who used hormone therapy had more breast cancer cases but fewer deaths from it. This study watched people over time, so it can show links but not prove cause.
See all research on Health screenings →